Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic myeloid leukemia patient populations covering 171 countries…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country,…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report the diagnosed prevalence of vitiligo for each country, as well as…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…
MARKET OUTLOOK NASH is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and…
Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal…
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…
MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted agents…
The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the…
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…
MARKET OUTLOOK With the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (…
MARKET OUTLOOKWith the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (…